8,335 Shares of Colgate-Palmolive Company $CL Purchased by Summit Wealth Group LLC Co.

Summit Wealth Group LLC Co. purchased a new position in shares of Colgate-Palmolive Company (NYSE:CL) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,335 shares of the company’s stock, valued at approximately $711,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Corient Private Wealth LP lifted its position in shares of Colgate-Palmolive by 29.0% during the second quarter. Corient Private Wealth LP now owns 639,604 shares of the company’s stock worth $58,639,000 after purchasing an additional 143,812 shares during the last quarter. Bank of America Corp DE purchased a new position in Colgate-Palmolive in the 2nd quarter worth about $567,483,000. Brandywine Financial Group increased its stake in Colgate-Palmolive by 35,612.3% in the 1st quarter. Brandywine Financial Group now owns 72,853 shares of the company’s stock worth $6,209,000 after buying an additional 72,649 shares during the period. SEB Asset Management AB bought a new stake in Colgate-Palmolive during the 1st quarter valued at about $91,149,000. Finally, Robinhood Asset Management LLC bought a new stake in Colgate-Palmolive during the 2nd quarter valued at about $11,554,000. 80.41% of the stock is currently owned by institutional investors.

Colgate-Palmolive Stock Down 2.1%

Colgate-Palmolive stock opened at $95.36 on Wednesday. The business’s 50-day moving average price is $89.73 and its 200 day moving average price is $89.77. The company has a quick ratio of 0.30, a current ratio of 0.96 and a debt-to-equity ratio of 11.23. The firm has a market cap of $75.80 billion, a price-to-earnings ratio of 37.40, a price-to-earnings-growth ratio of 4.55 and a beta of 0.31. Colgate-Palmolive Company has a 52 week low of $75.00 and a 52 week high of $99.33.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, October 30th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Colgate-Palmolive had a return on equity of 607.88% and a net margin of 9.65%. The company had revenue of $5.37 billion during the quarter, compared to the consensus estimate of $5.34 billion. During the same period in the previous year, the company posted $0.91 earnings per share. Colgate-Palmolive’s revenue for the quarter was up 4.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Colgate-Palmolive Company will post 3.91 earnings per share for the current year.

Colgate-Palmolive Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Tuesday, October 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, October 20th. Colgate-Palmolive’s payout ratio is currently 83.14%.

Insider Buying and Selling at Colgate-Palmolive

In related news, Director John Cahill sold 4,170 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $93.37, for a total transaction of $389,352.90. Following the sale, the director directly owned 28,373 shares of the company’s stock, valued at approximately $2,649,187.01. This represents a 12.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Panagiotis Tsourapas sold 10,000 shares of the firm’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $92.05, for a total transaction of $920,500.00. Following the sale, the chief operating officer owned 64,901 shares in the company, valued at approximately $5,974,137.05. This represents a 13.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.43% of the company’s stock.

More Colgate-Palmolive News

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Colgate-Palmolive beat third-quarter estimates, with sales up 4.6% year over year, and raised its EPS outlook while narrowing its 2026 sales outlook. Management cited resilient global demand and premium innovation, although costs remain a pressure. Q3 deep dive
• Positive Sentiment: Several analysts raised their targets after the results. Morgan Stanley lifted its target to $111 and kept an overweight rating; BNP Paribas Exane raised its target to $108 and reaffirmed outperform; RBC raised its target to $105 and maintained outperform. Analyst forecasts after Q3 earnings
• Neutral Sentiment: JPMorgan trimmed its target to $102 but retained an overweight rating. Barclays and Wells Fargo raised their targets to $95 while keeping equal-weight ratings, signaling limited upside at those firms’ estimates.
• Negative Sentiment: A valuation comparison noted that Colgate-Palmolive trades at a higher forward price-to-earnings multiple than Lululemon, raising questions about whether CL’s premium valuation is justified. Valuation comparison

Wall Street Analyst Weigh In

CL has been the subject of a number of research reports. Evercore boosted their price target on Colgate-Palmolive from $100.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Raymond James Financial raised their price target on shares of Colgate-Palmolive from $100.00 to $102.00 and gave the company an “outperform” rating in a report on Monday, August 3rd. BNP Paribas Exane restated an “outperform” rating and set a $108.00 target price (up from $97.00) on shares of Colgate-Palmolive in a research note on Monday. Jefferies Financial Group reissued a “hold” rating and set a $89.00 target price (up from $88.00) on shares of Colgate-Palmolive in a research report on Monday, August 3rd. Finally, JPMorgan Chase & Co. cut their price objective on Colgate-Palmolive from $104.00 to $102.00 and set an “overweight” rating on the stock in a report on Monday. Thirteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Colgate-Palmolive has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.

Colgate-Palmolive Profile

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill’s Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill’s Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.